Company news
Fortress Biotech, Inc. news in 2021
Fortress Biotech, Inc.'s news releases, calls and decks from 2021, newest first.
Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
December 20, 2021
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
December 15, 2021
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease
December 6, 2021
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 14, 2021
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition
October 12, 2021
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
October 5, 2021
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech
September 28, 2021
Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights
August 15, 2021
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 15, 2021
Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe
May 9, 2021
Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights
March 30, 2021
Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
February 25, 2021